Overview

Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer

Status:
Completed
Trial end date:
2016-09-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether or not the combination of cisplatin, irinotecan and radiation, followed by surgery, followed by oral Sutent, is effective and safe for patients with resectable esophageal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Collaborator:
Pfizer
Treatments:
Cisplatin
Irinotecan
Sunitinib